4Ellis J. The impact of lung cancer on patients and carers [J]. Chron Respir Dis,2012,9(1) :39-47. 被引量：1
5Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer., investigation- al approaches and clinical experience[J]. Lung Cancer, 2011,73(1):11- 17. 被引量：1
6Eisenhauer EA, Therasse P, Bogaerts J, et al. New re- sponse evaluation criteria in solid tumours: revised RE CIST guideline(version 1. 1)[J]. Eur J Cancer, 2009,45(2):228- 247. 被引量：1
7Kim AW, Boffa DJ, Wang Z, et al. An analysis, systematic review, and recta-analysis of the perioperative mortality after neoadiuvant therapy and pneumonectomy for non- small cell lung cancer [J]. J Thorac Cardiovasc Surg, 2012,143 (1) : 55-63. 被引量：1
8Hasturk S, Hatabay N, Ece F, et al. Gemcitabine, vinorel- bine,and cisplatin in the treatment of advanced non-small cell lung cancer[J]. Am J Clin Oncol, 2009,32 (3) :280- 285. 被引量：1
9Heigener DF. Non-small cell lung cancer in never-smok- ers..a new disease entity[J]. Onkologie,2011,34(4) :202- 207. 被引量：1
10Pallis AG,Georgoulias V. Is there a standard regimen for firs-line treatment of advanced/metastatic non-small-cell lung cancer? What has meta-analyses contributed to to- day's standard of care[J]. Lung Cancer,2012,75(3):269- 274. 被引量：1
